- Home
- ASTH vs ETNB Comparison
ASTH vs ETNB Comparison
Compare ASTH & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTH
- ETNB
- Stock Information
- Founded
- ASTH 1994
- ETNB 2018
- Country
- ASTH United States
- ETNB United States
- Employees
- ASTH N/A
- ETNB N/A
- Industry
- ASTH Professional Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ASTH Consumer Discretionary
- ETNB Health Care
- Exchange
- ASTH Nasdaq
- ETNB Nasdaq
- Market Cap
- ASTH 1.7B
- ETNB 1.5B
- IPO Year
- ASTH N/A
- ETNB 2019
- Fundamental
- Price
- ASTH $23.27
- ETNB $9.59
- Analyst Decision
- ASTH Strong Buy
- ETNB Strong Buy
- Analyst Count
- ASTH 8
- ETNB 8
- Target Price
- ASTH $53.29
- ETNB $26.43
- AVG Volume (30 Days)
- ASTH 292.7K
- ETNB 1.5M
- Earning Date
- ASTH 08-07-2025
- ETNB 08-08-2025
- Dividend Yield
- ASTH N/A
- ETNB N/A
- EPS Growth
- ASTH N/A
- ETNB N/A
- EPS
- ASTH 0.73
- ETNB N/A
- Revenue
- ASTH $2,250,574,000.00
- ETNB N/A
- Revenue This Year
- ASTH $41.46
- ETNB N/A
- Revenue Next Year
- ASTH $23.97
- ETNB N/A
- P/E Ratio
- ASTH $31.88
- ETNB N/A
- Revenue Growth
- ASTH 54.81
- ETNB N/A
- 52 Week Low
- ASTH $22.45
- ETNB $4.16
- 52 Week High
- ASTH $63.20
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- ASTH 43.11
- ETNB 41.01
- Support Level
- ASTH $22.45
- ETNB $9.82
- Resistance Level
- ASTH $23.96
- ETNB $10.48
- Average True Range (ATR)
- ASTH 1.07
- ETNB 0.49
- MACD
- ASTH -0.12
- ETNB -0.14
- Stochastic Oscillator
- ASTH 24.48
- ETNB 3.70
About ASTH Astrana Health Inc. Common Stock
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).